Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

BLTE stock hub

Belite Bio, Inc has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BLTEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

6.1B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BLTE

In the news

Latest news · BLTE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-16.9

P25 -105.6P50 -46.5P75 -3.1

ROIC-11.5

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BLTE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

176

Groups with data

Currency

USD

Showing 176 of 176 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001889109
Company name	Belite Bio, Inc
Country	United States
Country code	US
Cusip	07782B104
Employees	41
Employees Change	16%
Employees Change Percent	64
Enterprise value	$5.6B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2022-04-29
Isin	US07782B1044
Last refreshed	2026-05-10
Market cap	$6.1B
Market cap category	Mid-Cap
Price	$155
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	BLTE
Website	https://www.belitebio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1.27%
FCF yield	-0.61%
P/B ratio	7.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-77.6M
Net Income Growth Years	0%
Profit Per Employee	$-1.9M
ROA	-11.29
Roa5y	-22.68
ROCE	-10.93
ROE	-16.94
Roe5y	-37.11
ROIC	-11.48

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	152.7%
Cagr3y	76.41%
EPS Growth Years	0
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$780.6M
Cash	$492.4M
Current Assets	$494.3M
Current Liabilities	$9.9M
Debt	$429,000
Debt Equity	$0
Equity	$770.5M
Interest Coverage	-42,104
Liabilities	$10.1M
Long Term Assets	$286.3M
Long Term Liabilities	$188,000
Net Cash	$492M
Net Cash By Market Cap	$8.07
Net Cash Growth	240.22%
Net Debt Equity	$-0.64
Tangible Book Value	$770.5M
Tangible Book Value Per Share	$19.58
WACC	-2.31

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	50.02
Net Working Capital	$-7.8M
Quick ratio	49.9
Working Capital	$484.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.82%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	152.54%
200-day SMA	127.5
3Y total return	449.22%
50-day SMA	164.5
50-day SMA vs 200-day SMA	50over200
All Time High	200
All Time High Change	-22.56%
All Time High Date	2026-02-03
All Time Low	8.8
All Time Low Change	1,660%
All Time Low Date	2022-05-02
ATR	6.87
Beta	-1.19
Beta1y	0.84
Beta2y	0.76
Ch YTD	-3.18
High	157
High52	200
High52 Date	2026-02-03
High52ch	-22.56%
Low	152.5
Low52	56.1
Low52 Date	2025-07-02
Low52ch	176.08%
Ma50ch	-5.87%
Price vs 200-day SMA	21.46%
RSI	41.6
RSI Monthly	70.23
RSI Weekly	53.33
Sharpe ratio	1.97x
Sortino ratio	3.47
Total Return	-9.82%
Tr YTD	-3.18
Tr1m	-8.78%
Tr1w	0.02%
Tr3m	-17.56%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	3
Analyst Price Target Top	$197
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.63
Operating Income	$-84.2M
Price target	$198
Price Target Change	$27.84
Price Target Change Top	$27.41

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	18,514,421%
Float Percent	47.06%
Shares Insiders	1.79%
Shares Institutions	10.74%
Shares Out	39,339,960
Shares Qo Q	9.01%
Shares Yo Y	9.82%
Short Ratio	6.6
Short Shares	5.38

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-76.1M
Average Volume	111,798.3x
Bv Per Share	19.59
CAPEX	$-178,000
Ch1m	-8.78
Ch1w	0.02
Ch1y	152.5
Ch3m	-17.56
Ch3y	449.2
Ch6m	36.83
Change	-0.72%
Change From Open	-1.04
Close	156
Days Gap	0.32
Depreciation Amortization	184,000
Dollar Volume	9,287,998.7
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-84.2M
EBITDA	$-84M
EPS	$-2.31
F Score	2
FCF	$-37.2M
FCF EV Yield	-0.66x
FCF Per Share	$-0.94
Financing CF	663,233,000
Fiscal Year End	December
Founded	2,018
Investing CF	-305,107,000
Ipr	2,481.3
Iprfo	1,139
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-02
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-31
Ma150	147.5
Ma150ch	4.98%
Ma20	161.4
Ma20ch	-4.02%
Net CF	321,255,000
Next Earnings Date	2026-05-22
Open	156.5
Optionable	No
Position In Range	52.69
Post Close	154.9
Postmarket Change Percent	-0.56
Postmarket Price	$154
Ppne	777,000
Price Date	2026-05-08
Ptbv Ratio	7.91
Relative Volume	0.54x
Share Based Comp	38,919,000
Tr6m	36.83%
Us State	California
Volume	59,969

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BLTE pay a dividend?

Capital-return profile for this ticker.

Performance

BLTE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BLTE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.7%

Float: +47.1% of shares outstanding

Insider ownership

+1.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BLTE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

41.6

Neutral momentum band

Price vs 200-day MA

+21.5%

50/200-day relationship not available

Beta (5Y)

-1.19

Less volatile than the market

Sharpe ratio

1.97

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About BLTE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BLTE stock rating?

Belite Bio, Inc is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BLTE analysis?

The full report lives at /stocks/BLTE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BLTE?

The latest report frames BLTE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BLTE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.